Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide

被引:81
作者
Dorr, MB
Jabes, D
Cavaleri, M
Dowell, J
Mosconi, G
Malabarba, A
White, RJ
Henkel, TJ
机构
[1] Vicuron Pharmaceut, King Of Prussia, PA USA
[2] Vicuron Pharmaceut, Fremont, CA USA
[3] Vicuron Pharmaceut, Gerenzano, Varese, Italy
关键词
dosage regimen; pharmacodynamics; Gram-positive bacteria;
D O I
10.1093/jac/dki008
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The selection of a novel weekly dalbavancin dosage regimen was based on pharmacokinetic and pharmacodynamic data from humans and an animal model of infection. The results from the granuloma pouch model of infection suggested that dalbavancin concentrations >= 5 mg/ L are necessary for extended in vivo activity. Serum bactericidal activity assessments demonstrated that dalbavancin serum concentrations of approximately 20 mg/ L were bactericidal upon two-fold dilution. These data, coupled with simulations based on the pharmacokinetic profile derived from a clinical study in healthy volunteers, were used to design the weekly regimen studied in the initial efficacy trial. This efficacy study showed that a two-dose weekly regimen was well tolerated and associated with a higher clinical response rate than the comparator regimens. The data collectively support the further study of dalbavancin as a once-weekly regimen for the treatment of infections caused by Gram-positive bacteria.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 21 条
[1]   Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis [J].
Ahmed, A ;
Jafri, H ;
Lutsar, I ;
McCoig, CC ;
Trujillo, M ;
Wubbel, L ;
Shelton, S ;
McCracken, GH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :876-881
[2]   Pharmacological indices in antibiotic therapy [J].
Barger, A ;
Fuhst, C ;
Wiedemann, B .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (06) :893-898
[3]   Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection [J].
Boylan, CJ ;
Campanale, K ;
Iversen, PW ;
Phillips, DL ;
Zeckel, ML ;
Parr, TR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1700-1706
[4]   In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic [J].
Candiani, G ;
Abbondi, M ;
Borgonovi, M ;
Romanò, G ;
Parenti, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :179-192
[5]  
Dalhoff A, 1986, EXPT MODELS ANTIMICR, P123
[6]   In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria [J].
Goldstein, EJC ;
Citron, DM ;
Merriam, CV ;
Warren, Y ;
Tyrrell, K ;
Fernandez, HT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) :1968-1971
[7]   Teicoplanin therapy for Staphylococcus aureus septicaemia:: relationship between pre-dose serum concentrations and outcome [J].
Harding, I ;
MacGowan, AP ;
White, LO ;
Darley, ESR ;
Reed, V .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) :835-841
[8]   Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model [J].
Jabés, D ;
Candiani, G ;
Romanó, G ;
Brunati, C ;
Riva, S ;
Cavaleri, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1118-1123
[9]   In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent [J].
Jones, RN ;
Biedenbach, DJ ;
Johnson, DM ;
Pfaller, MA .
JOURNAL OF CHEMOTHERAPY, 2001, 13 (03) :244-254
[10]  
JORDAN MK, 2002, CLIN PHARMACOL THER, V71, P21